Defined stem cell signals, such as the protein Musashi homologue (MSI) have also been shown to be both genetically and epigenetically modified in cancers; for example, MSI2 translocation is associated with the accelerated phase in chronic myeloid leukemia, but MSI2 can also be epigenetically activated in the absence of mutations [10]. This evidence concerns the gene MSI2 and cancer.